Follow
Deb Schrag
Title
Cited by
Cited by
Year
How to build and interpret a nomogram for cancer prognosis
A Iasonos, D Schrag, GV Raj, KS Panageas
Journal of clinical oncology 26 (8), 1364-1370, 2008
27512008
Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial
E Basch, AM Deal, MG Kris, HI Scher, CA Hudis, P Sabbatini, L Rogak, ...
Journal of Clinical Oncology 34 (6), 557-565, 2016
23912016
Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment
E Basch, AM Deal, AC Dueck, HI Scher, MG Kris, C Hudis, D Schrag
Jama 318 (2), 197-198, 2017
20592017
Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population
JL Warren, CN Klabunde, D Schrag, PB Bach, GF Riley
Medical care 40 (8), IV-3-IV-18, 2002
20042002
American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer
AB Benson III, D Schrag, MR Somerfield, AM Cohen, AT Figueredo, ...
Journal of clinical oncology 22 (16), 3408-3419, 2004
18032004
Diagnosis and treatment of metastatic colorectal cancer: a review
LH Biller, D Schrag
Jama 325 (7), 669-685, 2021
16932021
AACR Project GENIE: powering precision medicine through an international consortium
AACR Project Genie Consortium, AACR Project GENIE Consortium, ...
Cancer discovery 7 (8), 818-831, 2017
14312017
Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry
KY Chung, J Shia, NE Kemeny, M Shah, GK Schwartz, A Tse, A Hamilton, ...
Journal of clinical oncology 23 (9), 1803-1810, 2005
14312005
Patients' expectations about effects of chemotherapy for advanced cancer
JC Weeks, PJ Catalano, A Cronin, MD Finkelman, JW Mack, NL Keating, ...
New England Journal of Medicine 367 (17), 1616-1625, 2012
13482012
Annual report to the nation on the status of cancer, 1975–2002, featuring population-based trends in cancer treatment
BK Edwards, ML Brown, PA Wingo, HL Howe, E Ward, LAG Ries, ...
Journal of the National Cancer Institute 97 (19), 1407-1427, 2005
12682005
The financial toxicity of cancer treatment: a pilot study assessing out‐of‐pocket expenses and the insured cancer patient's experience
SY Zafar, JM Peppercorn, D Schrag, DH Taylor, AM Goetzinger, X Zhong, ...
The oncologist 18 (4), 381-390, 2013
11402013
Primary care physicians who treat blacks and whites
PB Bach, HH Pham, D Schrag, RC Tate, JL Hargraves
New England Journal of Medicine 351 (6), 575-584, 2004
11132004
American Society of Clinical Oncology statement: a conceptual framework to assess the value of cancer treatment options
LE Schnipper, NE Davidson, DS Wollins, C Tyne, DW Blayney, D Blum, ...
Journal of Clinical Oncology 33 (23), 2563-2577, 2015
10262015
Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303)
HL Kindler, D Niedzwiecki, D Hollis, S Sutherland, D Schrag, H Hurwitz, ...
Journal of Clinical Oncology 28 (22), 3617-3622, 2010
10082010
Variations in morbidity after radical prostatectomy
CB Begg, ER Riedel, PB Bach, MW Kattan, D Schrag, JL Warren, ...
New England Journal of Medicine 346 (15), 1138-1144, 2002
10072002
Development of the National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)
E Basch, BB Reeve, SA Mitchell, SB Clauser, LM Minasian, AC Dueck, ...
Journal of the National Cancer Institute 106 (9), dju244, 2014
9682014
Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a …
AP Venook, D Niedzwiecki, HJ Lenz, F Innocenti, B Fruth, JA Meyerhardt, ...
Jama 317 (23), 2392-2401, 2017
8752017
The influence of hospital volume on survival after resection for lung cancer
PB Bach, LD Cramer, D Schrag, RJ Downey, SE Gelfand, CB Begg
New England Journal of Medicine 345 (3), 181-188, 2001
7882001
Validity and reliability of the US National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)
AC Dueck, TR Mendoza, SA Mitchell, BB Reeve, KM Castro, LJ Rogak, ...
JAMA oncology 1 (8), 1051-1059, 2015
7602015
American Society of Clinical Oncology guidance statement: the cost of cancer care
NJ Meropol, D Schrag, TJ Smith, TM Mulvey, RM Langdon Jr, D Blum, ...
Journal of Clinical Oncology 27 (23), 3868-3874, 2009
7012009
The system can't perform the operation now. Try again later.
Articles 1–20